VolitionRX Faces Pivotal Month with Key Data and Shareholder Vote

Biotechnology firm VolitionRX Ltd. enters a critical period marked by two significant corporate developments: the release of fresh clinical study results and the scheduling of an Annual General Meeting (AGM) to vote on substantial capital structure changes. The company’s shares are currently trading at $0.26.

VolitionRX has convened an AGM for March 31, where shareholders will be asked to approve two major proposals. The outcomes are expected to have a material impact on the company’s financial trajectory.

1. Reverse Stock Split Authorization: The board seeks shareholder approval to consolidate shares at a ratio ranging from 1-for-5 to 1-for-20. This move is primarily aimed at ensuring Read more...